Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps

A month after Freenome closed $300 million in financing, Roche has invested another $290 million in the diagnostics developer. The cash infusion comes as Freenome continues a pivotal test in colorectal cancer while it also readies for clinical trials in other types of cancer.